Pomerantz LLP is investigating claims on behalf of LENZ Therapeutics investors over whether the company and certain officers and/or directors engaged in securities fraud or other unlawful business practices. The inquiry follows Lenz's August 11, 2026, second-quarter results, which showed $5.5 million in total revenue, including $3.8 million from one-time, non-product global licensing milestones. Organic product sales for VIZZ, the company's primary commercial eye drop, were flat at $1.73 million, despite 9% quarter-over-quarter volume growth. On August 12, Bank of America downgraded Lenz from Buy to Neutral and reduced its price target from $31 to $7, citing a significantly slower-than-expected commercial launch for VIZZ. Lenz's stock price then fell sharply, damaging investors, the release said. Pomerantz asks investors to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, and provides information about joining the class action. The firm has offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv and says it has more than 85 years of experience in corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, whom the firm describes as the dean of the class action bar, Pomerantz pioneered securities class actions and has recovered numerous multimillion-dollar damages awards for class members. The release includes the firm's website, www.pomlaw.com, and the disclosures that it is attorney advertising and that prior results do not guarantee similar outcomes.